『Touching Base』のカバーアート

Touching Base

Touching Base

著者： Genetic Engineering & Biotechnology News (GEN)
無料で聴く

Touching Base is the dynamic podcast series from the editors of GEN (Genetic Engineering & Biotechnology News). Each episode features a rotating cast of senior editors including John Sterling, Kevin Davies, Julianna LeMieux, Alex Philippidis, Uduak Thomas, Corinna Singleman and Fay Lin who delve into emerging stories, exchange ideas, and debate the latest trends in biotech. Additionally, they talk to some of the leading voices in the industry about what's now and next.

Hosted on Acast. See acast.com/privacy for more information.

Genetic Engineering & Biotechnology News (GEN) 政治・政府 生物科学 科学
エピソード
  • BMS’s New Facility, Recursion–Genentech Partnership, Long-COVID and Persistent C.auris

    BMS’s New Facility, Recursion–Genentech Partnership, Long-COVID and Persistent C.auris
    2026/08/13
    Bristol Myers Squibb has selected Houston as the site for a new $2.3 billion multi-modal manufacturing campus designed to support drug product and finished goods manufacturing from late development through launch. Recursion, Roche, and its Genentech subsidiary have announced plans to co-develop a neuroscience discovery program based on the first validated target discovered through an AI map. Editors reminisce over the changes in science since the COVID-19 pandemic in light of a new large NIH-funded study that shows COVID-19 can reactivate dormant viruses, including Epstein-Barr and cytomegalovirus. In other infectious disease news, drug-resistant Candida auris was found to persist in hair follicles by exposing chitin, triggering interferon-γ that suppresses skin defenses and creates a niche for fungal colonization.Join GEN editors Corinna Singleman, PhD, Alex Philippidis, and Julianna LeMieux, PhD, for a discussion of the latest biotech and biopharma news. Listed below are links to the GEN stories referenced in this episode of Touching Base: BMS Chooses Houston for $2.3B Manufacturing FacilityBy Alex Philippidis, GEN Edge, Aug 10, 2026Next 10 U.S. Biopharma ClustersBy Alex Philippidis, GEN, Aug 12, 2026Recursion Partners with Genentech to Advance First Validated Neuro Target Discovered Through AI MapBy Alex Philippidis, GEN Edge, Aug 5, 2026COVID-19 Reactivates Dormant Viruses, Offering New Clues to Long COVIDGEN, Aug 5, 2026Trump’s Treatments: Regeneron’s Antibodies and Gilead’s Remdesivir ExplainedBy Alex Philippidis, GEN, Oct 5, 2020Lessons from the COVID Crisis: An Interview with Peter HotezBy Alex Philippidis, GEN Edge, Oct 19, 2022How to Conquer Coronavirus: Top 35 Treatments in DevelopmentBy Alex Philippidis, GEN, March 2, 2020Candida auris Persists in Hair Follicles, Hijacks Immune SignalingGEN, August 10, 2026The State of Biotech SummitSeptember 23, 2026 Touching Base Podcast Hosted by Corinna Singleman, PhD Behind the Breakthroughs Hosted by Jonathan D. Grinstein, PhD The State of Biologics Testing 2026Charles River Laboratories and GEN, June 10, 2026Subscribe to GEN’s newsletters Hosted on Acast. See acast.com/privacy for more information.
    続きを読む 一部表示
    38 分
  • Axiom’s Hong Kong Bet, Latigo’s Positive Phase II, and Base Editors for Huntington’s

    Axiom’s Hong Kong Bet, Latigo’s Positive Phase II, and Base Editors for Huntington’s
    2026/07/31

    In the business news section of this week’s episode, Axiom Biosciences recently announced its plans to go public and made headlines for its plans to do so on the Hong Kong Exchange rather than a U.S. market. We dig into the company’s reasoning. Then we turn our attention to Latigo’s report of positive Phase IIb data for its non-opioid acute pain candidate, and its plans to go through a planned IPO soon. Switching to some science news, we discuss findings from a study that identified genetic risk factors for fibromyalgia syndrome as well as links to other neurodegenerative, autoimmune, and metabolic diseases. And lastly, a potential base editing therapy for Huntington’s disease that has shown promise in mice.


    Join GEN editors Corinna Singleman, PhD, Alex Philippidis, and Uduak Thomas for a discussion of the latest biotech and biopharma news.

    Listed below are links to the GEN stories referenced in this episode of Touching Base: 


    StockWatch: Axiom CEO Explains Plans for Hong Kong IPO

    By Alex Philippidis, GEN Edge, July 27, 2026


    Latigo Reports Positive Phase IIb Data for Non-Opioid Acute Pain Candidate

    By Alex Philippidis, GEN Edge, July 30, 2026


    Genetic Study of Fibromyalgia Points to Neurological Basis

    GEN, July 29, 2026


    Base Editing Strategy Alleviates Huntington’s Disease in Mice

    GEN, July 29, 2026


    Touching Base Podcast 

    Hosted by Corinna Singleman, PhD 


    Behind the Breakthroughs 

    Hosted by Jonathan D. Grinstein, PhD 


    The State of Biologics Testing 2026

    Charles River Laboratories and GEN, June 10, 2026

    Hosted on Acast. See acast.com/privacy for more information.
    続きを読む 一部表示
    32 分
  • Parkinson’s in the Clinic, Insilico enters Phase III, Vertex Acquires Crinetics

    Parkinson’s in the Clinic, Insilico enters Phase III, Vertex Acquires Crinetics
    2026/07/17

    Promise hits Parkinson’s disease therapy, as a Phase I/II clinical study has demonstrated the feasibility of transplanting stem-cell-derived dopamine progenitor cells into the brain. In preclinical research, a new platform uses the brain’s fluid transport pathways to effectively deliver AAVs to therapeutic targets in mice. We’ll also cover the accelerating infrastructure moment for AI-driven drug discovery, with billion-dollar investments flowing into end-to-end platforms driven by models and compute, rather than single drug assets. In business, Insilico’s revenue leaps as the company’s AI-developed lead candidate moves to Phase III, while Vertex acquires Crinetics for $10 billion.


    Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news. 

    Listed below are links to the GEN stories referenced in this episode of Touching Base: 

    Engineered AAVs Harness Glymphatic System to Reach Brain Targets in Mice

    GEN, July 9, 2026

    Stem Cell Therapy Shows Promise in First Human Parkinson’s Disease Trial

    GEN, July 9, 2026

    Pharma Races to Scale AI as Billions Flow into Drug Discovery

    By Fay Lin, PhD, GEN Edge, July 6, 2026

    StockWatch: Insilico Projects Profit, Revenue Leaps as AI-Developed Lead Candidate Moves to Phase III

    By Alex Philippidis, GEN Edge, July 12, 2026

    Vertex Eyes Expansion Beyond Cystic Fibrosis with Planned $10B Crinetics Buyout

    By Alex Philippidis, GEN Edge, July 7, 2026

    Top 20 Drugs Heading for the Patent Cliff, 2026-2029

    By Alex Philippidis, GEN Magazine, Nov 1, 2025

    Touching Base Podcast 

    Hosted by Corinna Singleman, PhD 

    Behind the Breakthroughs 

    Hosted by Jonathan D. Grinstein, PhD 

    The State of Biologics Testing 2026

    Charles River Laboratories and GEN, June 10, 2026

    Hosted on Acast. See acast.com/privacy for more information.
    続きを読む 一部表示
    32 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません